[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336820-105":59,"doc-detail-336820-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-impact-of-durvalumab-on-biliary-tract-cancer-insights-from-real-world-clinical-data","Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data","","This study evaluates durvalumab combined with platinum and gemcitabine for biliary tract cancers in a real-world setting, aiming to confirm TOPAZ-1 results and connect disease molecular profiles with patient outcomes. A retrospective cohort of 102 BTC patients treated between 2022 and 2024 across six cancer centers in Austria and Germany received targeted DNA/RNA molecular profiling. Progression-free survival and overall survival were analyzed using log-rank tests and Cox regression. Disease control rate and response rate were 71.57% and 35.11%, with median PFS 6.51 months and OS 13.61 months.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-impact-of-durvalumab-on-biliary-tract-cancer-insights-from-real-world-clinical-data/336820/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-impact-of-durvalumab-on-biliary-tract-cancer-insights-from-real-world-clinical-data/336820.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on durvalumab for biliary tract cancer?","Question",{"text":112,"@type":113},"To assess the effectiveness of durvalumab with platinum and gemcitabine in real-world patients, confirm TOPAZ-1 results, and examine how molecular profiles relate to outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and what patient data were analyzed?",{"text":117,"@type":113},"A retrospective analysis of 102 biliary tract cancer patients treated from 2022 to 2024 at six cancer centers was performed, using targeted DNA and RNA molecular assays and survival analyses including PFS and OS.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key efficacy results reported?",{"text":121,"@type":113},"The study reported a disease control rate of 71.57% and an overall response rate of 35.11%, with median PFS of 6.51 months and median OS of 13.61 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336820,1790658599,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Cancer Immunology, Immunotherapy (2024) 73:251 [https://doi.org/10.1007/s00262-024-03842-y](https://doi.org/10.1007/s00262-024-03842-y)  \nExploring the impact of durvalumab on biliary tract cancer: insights from real‑world clinical data  \nPatrick Reimann1,2 · Ilektra‑Antonia Mavroeidi3,4,5 · Jonathan Burghofer6 · Hossein Taghizadeh8 · Gerald Webersinke6 · Stefan Kasper3,4 · Georg Schreil9 · Darius Morariu10 · Andreas Reichinger11 ·  \nHideo Andreas Baba4,7 · Patrick Kirchweger12,13,14 · Martin Schuler3,4,15 · Angela Djanani16 · Gerald W. Prager17 · Holger Rumpold11,12,14 · Magdalena Benda1,2 · Eva‑Maria Schneider1 · Sylvia Mink2,18 · Thomas Winder1,19 · Bernhard Doleschal11,12  \nReceived: 1 August 2024 / Accepted: 20 September 2024 / Published online: 3 October 2024 © The Author(s) 2024  \nAbstract  \nIntroduction This study assesses the effectiveness of durvalumab with platinum and gemcitabine for biliary tract cancers (BTC) . It aims to confirm the TOPAZ-1 trial results in a real-world context and explore the link between BTC molecular profiles and patient outcomes.  \nMethods A retrospective analysis was conducted on 102 BTC patients treated with durvalumab, platinum, and gemcitabineat five cancer centers in Austria and one in Germany from 2022 to 2024. Molecular profiling used targeted DNA and RNA assays. Clinical endpoints, including progression-free survival (PFS) and overall survival (OS), were assessed using log-rank tests and Cox regression, with correlations to second-line molecular-targeted therapies.  \nResults Among 102 patients, 60.8% had intrahepatic cholangiocarcinoma. The treatment achieved a disease control rate of 71.57% and an overall response rate of 35.11% . Median PFS was 6.51 months, and OS was 13.61 months. Patients under 65 had significantly better OS. Alterations in chromatin remodeling or homologous recombination repair genes were not predictive of survival benefit (HR: 0.45; p = 0.851 and HR: 1.63; p = 0.26, respectively) . Patients with molecular-informed  \nsecond-line therapy showed a trend toward survival benefit (HR: 0.23; p = 0.052) .  \nConclusion This study confirms the phase 3 trial results of durvalumab with platinum and gemcitabine, providing a substantial real-world dataset with detailed molecular characterization. No specific patient subgroup showed a markedly better response to durvalumab based on conventional NGS panels. Further research is needed to explore the link between immunotherapy responses and molecular subgroups.  \nKeywords Durvalumab · Homologous recombination repair (HRR) · Chromatin remodeling · Biliary tract cancer · Molecular-informed therapy · Precision oncology  \nIntroduction  \nBiliary tract cancer (BTC) constitutes a heterogeneous group of malignancies arising from various parts of the biliary system. This collective term includes carcinomas of the gallbladder/cystic duct (GBC) and cholangiocarcinomas (CCA) . CCAs can be further divided into three subtypes: intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA), depending on their exact anatomical origin [1, 2] .  \nAlthough, BTCs are quite rare, accounting for less than 1% of all malignant tumors, recent data have shown an  \nExtended author information available on the last page of the article  \nincrease in global incidence [2–4] . Prognosis remains poor with 5-year overall survival rates of approximately 5–15%[5, 6] . This is attributed to several reasons, primarily: 1) about two thirds of all patients are diagnosed with advanced/ metastatic disease and 2) patients undergoing potentially curative resection for localized tumors suffer from a high relapse rate [7] .  \nPalliative treatment in advanced BTCs was studied intensely over the past decades. However, after gemcitabine was first established as a valid treatment option in 1996, many subsequent trials with different treatment approaches yielded disappointing results [7, 8] . Progress was not achieved until the ABC-02 trial in 2010. This phase  \nIII study investigated ","cbCailoOvje8Tw11","https://ap.wps.com/l/cbCailoOvje8Tw11","pdf",1862265,12,"English","# Introduction\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What is the main goal of this study on durvalumab for biliary tract cancer?\",\"answer\":\"To assess the effectiveness of durvalumab with platinum and gemcitabine in real-world patients, confirm TOPAZ-1 results, and examine how molecular profiles relate to outcomes.\"},{\"question\":\"How was the study conducted and what patient data were analyzed?\",\"answer\":\"A retrospective analysis of 102 biliary tract cancer patients treated from 2022 to 2024 at six cancer centers was performed, using targeted DNA and RNA molecular assays and survival analyses including PFS and OS.\"},{\"question\":\"What were the key efficacy results reported?\",\"answer\":\"The study reported a disease control rate of 71.57% and an overall response rate of 35.11%, with median PFS of 6.51 months and median OS of 13.61 months.\"}]","Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data | PDF",1790016742,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad3f5b603a4a7dcdf3a6d0306e96f9b1.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/226c6e36055fc7089595df963a0df562.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5d7a08ed8a4286925c6858ecef2a7aa.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e6cbaaffa3b795d5ec01ee9de6d542a.webp",980,1301]